Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Rhea-AI Summary
Nurix Therapeutics (Nasdaq: NRIX), a clinical stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Arthur T. Sands, M.D., Ph.D., president and CEO, will deliver a corporate update on December 3, 2024, at 2:30 p.m. ET in New York City. The presentation will be available via live webcast through the company's website, with the recording accessible for 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – NRIX
On the day this news was published, NRIX declined 1.04%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the Piper Sandler 36th Annual Healthcare Conference, at 2:30 p.m. ET on Tuesday, December 3, 2024, in New York City.
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available for 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
When is Nurix Therapeutics (NRIX) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Nurix Therapeutics (NRIX) presentation at the Piper Sandler Conference?
What type of drugs is Nurix Therapeutics (NRIX) developing?
